• Mira Pharmaceuticals reported positive unblinded results from its completed Phase 1 trial of oral Ketamir-2; no future presentation was disclosed.
• Study met key early-stage objectives, with results supporting a favorable safety and tolerability profile in healthy volunteers.
• Data also indicated drug exposure consistent with potential once-daily dosing, subject to further clinical testing.
• Company is preparing to submit Phase 2a materials to FDA to start a mid-stage study in chemotherapy-induced peripheral neuropathy under its active IND.
• DEA review concluded Ketamir-2 is not classified as a controlled substance, removing a potential regulatory constraint ahead of later-stage development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022704), on May 13, 2026, and is solely responsible for the information contained therein.